Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The European Association for the Study of Diabetes (EASD) 2026 Annual Meeting in Milan (Sept 28–Oct 2) is set to shake up diabetes care. A new EASD/ADA consensus on type 2 diabetes (T2D) management will recommend GLP-1 receptor agonists and/or SGLT2 inhibitors as first-line therapy — potentially sidelining metformin. Major trial results for retatrutide, tirzepatide, orforglipron, survodutide, and trevogrumab will also be unveiled.
The EASD 2026 Annual Meeting in Milan is shaping up to be a landmark moment for diabetes care. A finalized joint EASD/ADA consensus on T2D management — the first update since 2022 — will be presented and simultaneously published. The big headline: GLP-1 receptor agonists and/or SGLT2 inhibitors may be recommended as first-line therapy, with metformin's long-standing dominance under serious scrutiny. New EASD guidelines on continuous glucose monitoring (CGM) in T2D and updated liver screening recommendations are also on the agenda.
On the type 1 diabetes (T1D) front, sessions will cover autoantibody-based screening, teplizumab-led early intervention, stem cell-derived islet transplantation, and advances in closed-loop insulin delivery. A separate symposium will explore whether an exercise-focused lifestyle intervention — without drugs — can achieve remission in early-onset T2D patients aged 18–45.
Key Takeaways:
Why it matters: These updates could fundamentally change how clinicians approach diabetes from day one — moving beyond glucose control toward comprehensive cardiovascular and organ protection, while a wave of next-gen incretin therapies continues to expand the treatment toolkit.
